PMV Pharmaceuticals, Inc. (PMVP) Reports 48% Response Rate in Ovarian Cancer Trial
PMV Pharmaceuticals reported Phase 2 trial results for its ovarian cancer treatment, showing a 48% response rate in 65 patients and a 36% rate in 168 evaluable patients. The company plans to submit a New Drug Application in Q1 2027.
How this was made

The 30-second read
Why it matters
The disclosed ORR of 48% in a hard‑to‑treat population is a strong efficacy signal that could accelerate the upcoming NDA submission.
Market read
First report of pivotal trial data; potential catalyst for share price ahead of regulatory filing.
What to watch
Small patient cohort and lack of comparator arm could temper enthusiasm.
Background
PMV Pharmaceuticals is a clinical‑stage biotech focused on oncology therapies.
Ticker impact
Phase 2 trial reports 48% ORR in platinum‑resistant ovarian cancer patients, new data not previously disclosed.
likely upward pressure as investors price in potential approval and market opportunity.
First public disclosure of pivotal efficacy data; biotech stocks typically react strongly to such news.
Market effects
May lift sentiment in the oncology biotech sector.
Limited to US biotech investors.
Modest, primarily affecting niche oncology investors.
Counterpoint
Skeptics may question durability of response and regulatory risk.
Key entities
- companyPMV Pharmaceuticals, Inc.
Clinical‑stage oncology biotech.